France · Delayed Price · Currency is EUR Guerbet Company Description
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide.
It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid.
The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; Ready-Box, a contrast media warmer; MRI accessories and consumables for diagnostic imaging; OptiProtect 3S, a suite of services and support solution; Conray/Cysto-Conray, an iothalamate meglumine injection contrast agent for CT; Micropaque/Microtrast, a barium sulfate contrast agent for CT; Optiray, an ioversol contrast agent for CT and Cath lab; Telebrix Gastro, a meglumine ioxitalamate contrast agent for CT; and Xenetix/ScanBag by Xenetix, an Iobitridol contrast agent for CT and Cath lab.
In addition, it offers OptiBolus, which allows for a uniform vascular enhancement throughout the procedure; OptiOne, a single head injector; OptiVantage Multi-use, an optimal power injector for X-ray procedures; OptiVantage, a dual-head CT contrast delivery injector; Illumena Néo, a multi-mode contrast delivery injector; Lipiodol Ultra Fluid, an iodinated ethyl ester of fatty acids of poppy seed oil; Qitexio, a range of lipiodol resistant medical devices consisting of medical syringes and a stopcock; Lipiodol Ultra Fluid for use in interventional radiology and women’s health; and Patent Blue V, a pharmaceutical drug for breast cancer.
The company was founded in 1901 and is headquartered in Villepinte, France.
| Country | France |
| Founded | 1901 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2,746 |
| CEO | Karim Boussebaa |
Contact Details
Address: 15 rue des Vanesses Villepinte, 93420 France | |
| Phone | 33 1 45 91 50 00 |
| Website | guerbet.com |
Stock Details
| Ticker Symbol | GBT |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0000032526 |
| SIC Code | 3844 |
Key Executives
| Name | Position |
|---|---|
| Karim Boussebaa | Chief Executive Officer |
| Philippe Bourrinet | Chief Pharmacist, Deputy Chief Executive Officer, Senior Vice President of Development, Medical and Regulatory Affairs and Deputy MD |
| Jerome Estampes | Group Chief Financial Officer and SVice President of Business Development & Licensing |
| Charlotte Bamiere | General Counsel and SVice President of Legal Affairs and Compliance |
| Christine Allard | Senior Vice President of Public Affairs and Corporate Communications |
| Eva Ohlsson | Senior Vice President of Human Resources and CSR |
| Francois Nicolas | SVice President of Research, Development, Innovation and AI |
| Valérie Brissart | Senior Vice President of Diagnostic Imaging |
| François Convenant | SVice President of Interventional Radiology and Global VP of Commercial and Interventional Imaging |
| Eric Kummer | Senior Vice President of Technical Operations |